Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Pre-Market Trading 11-22 05:49:20 EST

0.7717

-0.0357

-4.42%

盘前0.7717

+0.00000.00%

05:46 EST

High0.8346	Low0.7633	Vol3.66M
Open0.8043	D1 Closing0.8074	Amplitude8.83%
Mkt Cap278.96M	Tradable Cap140.56M	Total Shares361.49M
T/O2.89M	T/O Rate2.01%	Tradable Shares182.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":0.7717,"timestamp":1732222800000,"preClose":0.8074,"halted":0,"volume":3658063,"hourTrading":{"tag":"盘前","latestPrice":0.7717,"preClose":0.7717,"latestTime":"05:46 EST","volume":20,"amount":15.434000000000001,"timestamp":1732272365832},"delay":0,"floatShares":182142700,"shares":361492295,"eps":-0.743931,"marketStatus":"Pre-Market Trading","change":-0.0357,"latestTime":"11-22 05:49:20 EST","open":0.8043,"high":0.8346,"low":0.7633,"amount":2888677.9730746,"amplitude":0.088308,"askPrice":0.7717,"askSize":2980,"bidPrice":0.7088,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.743931,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":0.7717,"preHourTrading":{"tag":"盘前","latestPrice":0.7717,"preClose":0.7717,"latestTime":"05:46 EST","volume":20,"amount":15.434000000000001,"timestamp":1732272365832},"postHourTrading":{"tag":"盘后","latestPrice":0.77,"preClose":0.7717,"latestTime":"19:53 EST","volume":67879,"amount":52610.9046,"timestamp":1732236832295},"volumeRatio":1.1082005610680228,"impliedVol":0.5893,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2485179313","title":"Lexicon Pharmaceuticals Appoints Ivan Cheung to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2485179313","media":"TIPRANKS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485179313?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:33","pubTimestamp":1732138430,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) has shared an update. Lexicon Pharmaceuticals has appointed Ivan H. Cheung, a seasoned executive with extensive...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-appoints-ivan-cheung-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-appoints-ivan-cheung-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485173547","title":"Lexicon Appoints Ivan H. Cheung to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2485173547","media":"THOMSON REUTERS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485173547?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:05","pubTimestamp":1732136747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA6M0XHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485632173","title":"Press Release: Lexicon Appoints Ivan H. Cheung to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2485632173","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485632173?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:05","pubTimestamp":1732136700,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, Nov. 20, 2024  -- Lexicon Pharmaceuticals, Inc.  today announced that Ivan H. Cheung has been elected to its Board of Directors.Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth -- a growth investing platform within global asset manager TPG -- since September 2023.Mr. Cheung previously served in a series of executive leadership positions at Eisai Co., Ltd., over the course of 18 years, most recently as chairman and chief executive officer of Eisai Inc. from 2016 to July 2023 and strategic advisor from August to December 2023. Prior to joining Eisai, Mr. Cheung spent seven years with Booz Allen Hamilton, Inc., where he held a variety of consulting positions. Mr. Cheung holds a B.S.E from Duke University and an M.B.A. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4022","BK4139","BK4585","TM","BK4588","R","BK4232","BK4099","03160","LXRX"],"gpt_icon":0},{"id":"2484110627","title":"Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110627","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110627?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:07","pubTimestamp":1731935222,"startTime":"0","endTime":"0","summary":"As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of Lexicon Pharmaceuticals, Inc.  investors who have held the stock for three years as it declined a whopping 80%. That would certainly shake our confidence in the decision to own the stock. Unfortunately the share price momentum is still quite negative, with prices down 53% in thirty days. Importantly, this could be a market reaction to the recently released financial results. You can check out the latest numbers in our company report. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-nasdaq-lxrx-investor-130702815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","LXRX","PSQ","NQmain","MNQmain",".IXIC","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","TQQQ","IE00BKPKM429.USD","LU2210150020.SGD","QLD","SQQQ","BK4588","IE00BGHQF748.EUR","NDAQ","QID","BK4585"],"gpt_icon":1},{"id":"2483878243","title":"Lexicon Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $4 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2483878243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483878243?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:30","pubTimestamp":1731583811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2483894000","title":"Lexicon Pharmaceuticals (LXRX) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2483894000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483894000?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:20","pubTimestamp":1731504004,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-gets-a-buy-from-piper-sandler-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-gets-a-buy-from-piper-sandler-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2483215001","title":"Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483215001","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483215001?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:34","pubTimestamp":1731501240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 07:34 ET (12:34 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2483231090","title":"Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483231090","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483231090?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:20","pubTimestamp":1731482411,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Lexicon Pharmaceuticals Inc  completed the resubmission of their NDA for inep for glycemic control in people with type one diabetes and chronic kidney disease.The company has two major assets undergoing late-stage clinical development, with significant progress in both a phase three study for Solosin in hypertrophic cardiomyopathy and a phase two B study for LX 9,211 in diabetic peripheral neuropathic pain.The company has a strong cash position with $258.4 million in cash and investments, not including the recent $25 million from the Beatrice deal.Lexicon Pharmaceuticals Inc  is actively preparing for an IND filing for their novel drug candidate LX 9,851, targeting obesity and associated cardiometabolic disorders, by mid-2025.Q: Regarding the pain program, are you expecting a larger placebo-adjusted efficacy separation than in the prior phase 2A?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F51HtmbQRBPEbFtj3EJsGg--~B/aD0zMzc7dz0zMzc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d39692b9db1249795735b99d28506197","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F51HtmbQRBPEbFtj3EJsGg--~B/aD0zMzc7dz0zMzc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d39692b9db1249795735b99d28506197"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-inc-lxrx-q3-072011612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX"],"gpt_icon":0},{"id":"2483606211","title":"Lexicon Pharmaceuticals Inc reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483606211","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483606211?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:27","pubTimestamp":1731454034,"startTime":"0","endTime":"0","summary":"* Lexicon Pharmaceuticals Inc    reported a quarterly adjusted loss of 18 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -21 cents.  The mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2483094560","title":"Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094560","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483094560?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:25","pubTimestamp":1731450305,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals  came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.88%. A quarter ago, it was expected that this drugmaker would post a loss of $0.18 per share when it actually produced a loss of $0.17, delivering a surprise of 5.56%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Lexicon , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.75 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 44.18%. This compares to year-ago revenues of $0.16 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/26ddEdIk.0DefsBmi91u3Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/26ddEdIk.0DefsBmi91u3Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-lxrx-reports-q3-222505799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX"],"gpt_icon":0},{"id":"2483050828","title":"Lexicon: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050828","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050828?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:25","pubTimestamp":1731446732,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas  — THE WOODLANDS, Texas  — Lexicon Pharmaceuticals Inc.  on Tuesday reported a loss of $64.8 million in its third quarter.On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 18 cents.The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.The drugmaker posted revenue of $1.8 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $3.1 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-q3-earnings-snapshot-212532650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX"],"gpt_icon":0},{"id":"2483105291","title":"Lexicon Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $1.800M Miss $2.929M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483105291","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483105291?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:08","pubTimestamp":1731445698,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent.  The company reported quarterly sales of $1.800 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41919052/lexicon-pharmaceuticals-q3-2024-gaap-eps-0-18-misses-0-17-estimate-sales-1-800m-miss-2-929m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Lexicon Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $1.800M Miss $2.929M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2483676054","title":"Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2483676054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483676054?lang=en_us&edition=fundamental","pubTime":"2024-11-13 04:30","pubTimestamp":1731443424,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Lexicon (LXRX) Pharmaceuticals is normal with calls leading puts 11:2. Implied volatility suggests the market is ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-pharmaceuticals-options-imply-14-8-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-pharmaceuticals-options-imply-14-8-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"gpt_icon":0},{"id":"2482469198","title":"Lexicon Pharmaceuticals Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482469198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482469198?lang=en_us&edition=fundamental","pubTime":"2024-11-09 08:26","pubTimestamp":1731111965,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc  expected to post a loss of16cents a share - Earnings Preview Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to show a rise in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241109:nL8N3MG02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2481606066","title":"Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481606066?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, Nov.  06, 2024  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975653/0/en/Lexicon-Pharmaceuticals-to-Participate-in-the-Jefferies-London-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2481652264","title":"Lexicon announces JASN publishes sotagliflozin data","url":"https://stock-news.laohu8.com/highlight/detail?id=2481652264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481652264?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:50","pubTimestamp":1730843419,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced the peer-reviewed Journal of American Society of Nephrology, or JASN, has published a research paper analyzing the efficac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-jasn-publishes-sotagliflozin-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-jasn-publishes-sotagliflozin-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2481022656","title":"Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2481022656","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481022656?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:05","pubTimestamp":1730840700,"startTime":"0","endTime":"0","summary":"People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin , the primary endpoint, as people with T1D who do not have CKD. Sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis  among a small number of DKA events. The findings from the study, “Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD,” concluded that people with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin , the primary endpoint of the underlying clinical trials, as T1D patients who do not have CKD. Further, the findings show that sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis  among a small number of DKA events.Results were generally similar in inTandem3 except systolic BP was significantly ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z4OL.khIWMuwruXdjunukQ--~B/aD01MDt3PTE2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0ead9423451a49118cdc67bcbc937222","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z4OL.khIWMuwruXdjunukQ--~B/aD01MDt3PTE2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0ead9423451a49118cdc67bcbc937222"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/published-data-journal-american-society-210500951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4201","BK4588","BK4107","BK4585","LXRX","LU1162221912.USD","LU0162691827.USD","AFG","LU0320765646.SGD","BP","LU0072461881.USD","LU1829250122.USD","BK4139","BK4117"],"gpt_icon":0},{"id":"2481068334","title":"Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481068334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481068334?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:57","pubTimestamp":1730818620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2024 09:57 ET (14:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2481506297","title":"Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506297?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, Nov.  05, 2024  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2024 financial results on Tuesday, November 12, 2024 after the mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974885/0/en/Lexicon-Pharmaceuticals-to-Host-Third-Quarter-2024-Financial-Results-Conference-Call-and-Webcast-on-November-12-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","HST","BK4588","LXRX","BK4218","BK4181"],"gpt_icon":0},{"id":"2480580525","title":"Lexicon Pharmaceuticals Inc    expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480580525","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480580525?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:38","pubTimestamp":1730734701,"startTime":"0","endTime":"0","summary":"* Lexicon Pharmaceuticals Inc     is expected to show a rise in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2024   * The The Woodlands Texas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Lexicon Pharmaceuticals Inc    expected to post a loss of 16 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.272},{"period":"1month","weight":-0.6022},{"period":"3month","weight":-0.5783},{"period":"6month","weight":-0.5236},{"period":"1year","weight":-0.2985},{"period":"ytd","weight":-0.4956}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.042931},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.058519},{"month":3,"riseRate":0.5,"avgChangeRate":-0.006016},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.011119},{"month":5,"riseRate":0.52,"avgChangeRate":0.035958},{"month":6,"riseRate":0.64,"avgChangeRate":0.119795},{"month":7,"riseRate":0.48,"avgChangeRate":0.017089},{"month":8,"riseRate":0.24,"avgChangeRate":-0.027412},{"month":9,"riseRate":0.32,"avgChangeRate":0.002483},{"month":10,"riseRate":0.52,"avgChangeRate":-0.007629},{"month":11,"riseRate":0.36,"avgChangeRate":-0.045597},{"month":12,"riseRate":0.5,"avgChangeRate":0.078876}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}